CGON vs KRYS: stock comparison and AI forecast
Cg Oncology, Inc. (CGON) and Krystal Biotech, Inc. (KRYS) compared on price performance, valuation, profitability and the daily AI forecast. · Alpha · vs market
Share
CGON Cg Oncology, Inc.
- Market Cap
- $6.74B
- P/E Ratio
- –
- Size
- mid-cap
- AI Forecast
KRYS Krystal Biotech, Inc.
- Price
- $300.88 +1.4% · 6M
- Market Cap
- $8.92B
- P/E Ratio
- 40.9x
- Size
- mid-cap
- AI Forecast
Which one does the AI model favor?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
Key facts
- KRYS is 1.3 times larger than CGON by market capitalization ($8.92B against $6.74B).
- KRYS turns 47.9% of its revenue into net income, against -3851.1% for CGON.
- KRYS carries 0.10 times debt per unit of equity, against 0.06 times for CGON.
- Both companies share the SEC industry classification Biological Products, (No Diagnostic Substances).
Fundamentals side by side
Trailing twelve months.
Valuation & Market
| Metric | CGON | KRYS |
|---|---|---|
| Market Cap | $6.74B | $8.92B |
| P/E Ratio | – | 40.89x |
| P/B Ratio | 6.80x | 6.21x |
| EPS | $-3.22 | $7.36 |
| Book Value/Share | $11.18 | $48.44 |
| Revenue/Share | $0.07 | $15.86 |
| FCF/Share | $-2.13 | $10.46 |
Profitability & Margins
| Metric | CGON | KRYS |
|---|---|---|
| ROE | -24.0% | 15.7% |
| ROA | -22.7% | 14.2% |
| ROIC | -26.5% | 15.8% |
| Operating Margin | -4293.5% | 48.4% |
| Net Margin | -3851.1% | 47.9% |
| EBT Margin | -4293.5% | 55.1% |
| Tax Rate | 0.1% | 13.0% |
Financial Health
| Metric | CGON | KRYS |
|---|---|---|
| Current Ratio | 21.70x | 7.89x |
| Quick Ratio | 21.68x | 7.53x |
| D/E Ratio | 0.06x | 0.10x |
| Financial Leverage | 1.06x | 1.10x |
| Interest Coverage | -1317.7x | – |
| Working Capital | $961M | $980M |
Cash Flow
| Metric | CGON | KRYS |
|---|---|---|
| Operating Cash Flow | -$187M | $324M |
| Free Cash Flow | -$189M | $310M |
| Capital Spending | -$2M | -$14M |
| OCF Growth YoY | – | 83.8% |
| FCF Growth YoY | – | 87.3% |
| FCF/Sales | -3068.0% | 66.0% |
| CapEx/Sales | 30.7% | 3.0% |
Operational Efficiency
| Metric | CGON | KRYS |
|---|---|---|
| Asset Turnover | 0.01x | 0.30x |
| Receivables Turnover | 9.3x | 3.5x |
| Fixed Assets Turnover | 0.4x | 3.1x |
| Days Sales Outstanding | 39 days | 103 days |
Income Statement
| Metric | CGON | KRYS |
|---|---|---|
| Total Revenue | $6M | $470M |
| Operating Income | -$265M | $228M |
| Net Income | -$237M | $225M |
| R&D Expense | $168M | $60M |
| SG&A Expense | – | $156M |
Dividend & Shareholder Information
| Metric | CGON | KRYS |
|---|---|---|
| Shares Outstanding | 89M | 30M |
| Net Income Growth | – | 13.2% |
| EPS Growth | – | 1.7% |
CGON vs KRYS: stock comparison and AI forecast
Which is bigger, CGON or KRYS?
KRYS is 1.3 times larger than CGON by market capitalization ($8.92B against $6.74B).
Which one does Intratio's AI model rank higher, CGON or KRYS?
Intratio's model scores both stocks every trading day. Sign in to see their current direction; the exact ratings and forecasts come with a plan or a free follow slot.
More comparisons
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.